Long-acting growth hormone deficiency treatments will boost market growth
New research indicates that the global market for growth hormone deficiency (GHD) treatment will rise in value from $1.26 billion in 2014 to reach around $1.88 billion by 2024, representing a moderate compound annual growth rate (CAGR) of 4.08%.
According to research and consulting firm GlobalData’s latest report, the increase, which will occur across the seven major countries of the USA, France, Germany, Italy, Spain, UK and Japan, will be primarily driven by the launch of long-acting growth hormone biobetters, which are expected to begin entering the market in 2017.
GlobalData’s senior analyst covering cardiovascular and metabolic disorders, Lakshmi Dharmarajan, says the less frequent dosing schedules of these drugs will be attractive to patients, offering improved compliance and adherence outcomes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze